Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Dupixent

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

Investors Business Daily

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Investors Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.

Sanofi stock undercut its 50-day line Thursday despite Dupixent outperformance as its earnings lagged Wall Street's expectations.

Investors Business Daily

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.

Investors Business Daily

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Investors Business Daily

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi

Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Investors Business Daily

Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again

Sanofi stock rose Thursday on strong revenue growth for the company's allergic conditions treatment, Dupixent.

Investors Business Daily

5 Non-Cyclical Stocks to Buy Now if You're Worried About a Recession

As surging inflation and energy prices foster recessionary fears, it could be wise to bet on non-cyclical stocks because they tend to outperform the broader market when economic growth slows. Given the inelastic demand for their companies’ products, we think the shares of United Parcel Service (UPS), British American Tobacco…

StockNews.com

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

67 stories

Regeneron Pharmaceuticals Inc

British American Tobacco Plc

19 stories

United Parcel Service, Inc.

19 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.